Dostarlimab

In a small study, patients with rectal cancer got six months of immunotherapy treatment — and doctors say their tumors disappeared.

"The treatment targets a subtype of rectal cancer that has the DNA repair system not working. But they say that seeing complete remission in 100% of patients tested is a very promising early signal. It was administered to each patient every three weeks for six months, and it works by exposing cancer cells so the immune system can identify and destroy them. "The implications for quality of life are substantial, especially in those where standard treatment would impact childbearing potential. These same remarkable results would be seen in 14 patients to date. That's when doctors gave her the good news: She was now cancer-free.

On how the drug works to treat cancer: This drug is one of a class of drugs called immune checkpoint inhibitors. These are immunotherapy medicines that work not ...

You may click on “Your Choices” below to learn about and use cookie management tools to limit use of cookies when you visit NPR’s sites. If you click “Agree and Continue” below, you acknowledge that your cookie choices in those tools will be respected and that you otherwise agree to the use of cookies on NPR’s sites. NPR’s sites use cookies, similar tracking and storage technologies, and information about the device you use to access our sites (together, “cookies”) to enhance your viewing, listening and user experience, personalize content, personalize messages from NPR’s sponsors, provide social media features, and analyze NPR’s traffic.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair ...

Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. In total, 153 patients were enrolled in cohort A1 and 161 patients in cohort A1, of which 143 patients and 156 patients were evaluable for efficacy, respectively. The median duration of response (DOR) was not reached (NR; range, 1.18+ to 47.21+) in cohort A1, and was 19.4 months (range, 2.8-47.18+) in cohort A2. At the annual meeting, Oaknin reported on the efficacy and safety of dostarlimab monotherapy in 2 expansion cohorts from the GARNET study that enrolled patients with advanced/recurrent endometrial cancer—in particular, from the third pre-specified interim analysis. Both indications are approved under accelerated approval based on tumor response rate and durability of response. “For patients with disease progression that occurs on or after first-line therapy, overall survivor is typically less than 1 year and there is no standard second-line therapy. Similarly, time to PR in both cohorts were 2.69 months and 2.79 months. J Clin Oncol. 2022;40(suppl 16):5509. doi:10.1200/JCO.2022.40.16_suppl.5509 Median overall survival (OS) for cohort A1 was NR (95% CI, 27.1-NR), with a probability of OS at 24 months of 60.5% (95% CI, 51.5%-68.4%), compared with a median OS of 16.9 months (95% CI, 13.0-21.8) and probability of 38.4% (95% CI, 32.0%-44.6%) in cohort A2. In cohort A1, median progression-free survival (PFS) was 6.0 months (95% CI, 4.1-18.0), with a probability for PFS at 24 months of 40.1% (95% CI, 31.6%-48.4%). In cohort A2, median PFS was 2.7 months (95% CI, 2.6-2.8), with a probability of 9.4% for PFS at 24 months (95% CI, 5.2%-15.0%). In the trial, patients with endometrial cancer were enrolled in cohort A1 (dMMR/MSI-H) or cohort A2 (MMRp/MSS). Median follow-up for both cohorts was 27.6 months and 33.0 months, respectively. Dostarlimab (Jemperli) monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient (dMMR)/microsatellite instability–high (MSI-H) or mismatch repair proficient (MMRp)/mismatch stable (MSS) disease, according to data from 2 expansion cohorts in the GARNET trial (NCT02715284) presented at the 2022 ASCO Annual Meeting.

In a small clinical trial, 18 patients took the drug Dostarlimab for six months, and all of them had their cancer vanished.

"It is noteworthy that they were all in similar stages of their cancer. According to doctors, the patients, during the trial, took Dostarlimab every three weeks for six months. According to the New York Times, individuals in the clinical experiment previously received treatments such as chemotherapy, radiation, and invasive surgery, all of which could cause bowel, urinary, and sexual dysfunction.

In a clinical trial in the United States, all the participating rectal cancer patients were cured. The medical marvel took place in the country's famous ...

The overall five-year survival rate for rectal cancer is 63 per cent. The rectum is a part of the body's elaborate digestive system. In a clinical trial in the United States, all the participating rectal cancer patients were cured.

The doctor behind a breakthrough New York City-based cancer study said that the astounding results are unlike anything he — or anyone — has seen before, as.

Usually, patients with rectal cancer must endure surgery and chemotherapy — but there was no need for either of those after patients took the drug. The results that have their physicians equally as excited, and ready to see how else this drug could help. Doctors want to repeat the results with a larger group, saying its too early to say that the cancer is permanently gone. The patients — 19 in all, including six more that were included Monday and another one Tuesday — participated in a small clinical trial through Manhattan’s Memorial Sloan Kettering. Each had a specific form of rectal cancer, and took an experimental cancer drug called Dostarlimab. The patients don’t need convincing though. Now, all of the 19 are in complete remission, cancer-free with minimal side-effects.